Psychosis with use of amphetamine drugs, methylphenidate and atomoxetine in adolescent and adults
Background Use of psychostimulants and relative drugs has increased worldwide in treatment of attention-deficit hyperactivity disorder (ADHD) in adolescents and adults. Recent studies suggest a potential association between use of psychostimulants and psychotic symptoms. The risk may not be the same...
Main Authors: | François Montastruc, Vanessa Rousseau, Agnes Sommet, Alexis Revet, Genevieve Durrieu, Jacques Hamard, Philippe Garcia, Antoine Yrondi |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2024-04-01
|
Series: | BMJ Mental Health |
Online Access: | https://ebmh.bmj.com/content/27/1/e300876.full |
Similar Items
-
Atomoxetine and Methylphenidate Treatment in ADHD
by: Snircova E., et al.
Published: (2015-05-01) -
Safety profiles of methylphenidate, amphetamine, and atomoxetine: analysis of spontaneous reports submitted to the food and drug administration adverse event reporting system
by: Wei Wei, et al.
Published: (2023-08-01) -
Daily methylphenidate and atomoxetine treatment impacts on clock gene protein expression in the mouse brain.
by: Baird, A, et al.
Published: (2013) -
Treatment outcomes after methylphenidate in adults with attention-deficit/hyperactivity disorder treated with lisdexamfetamine dimesylate or atomoxetine
by: Joseph A, et al.
Published: (2016-03-01) -
Rise, and pronounced regional variation, in methylphenidate, amphetamine, and lisdexamfetamine distribution in the United States
by: Sneha M. Vaddadi, et al.
Published: (2021-12-01)